Ron Cohen

Ron Cohen, M.D., is Chief Executive Officer of Oryon Cell Therapies. Before joining Oryon, Dr. Choen was President, Chief Executive Officer and Founder of Acorda Therapeutics, Inc., a public biotechnology company that developed and commercialized therapies for disorders of the nervous system, including Parkinson’s disease and multiple sclerosis. Merz Therapeutics acquired the company’s commercial portfolio in 2024. Previously, Dr. Cohen was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses. He served as Director and Chair of the Boards of both the Biotechnology Innovation Organization (BIO) and the New York Biotechnology Association (NYBA), where he advocated on behalf of the biotechnology industry before political leaders, patient organizations, and other constituencies.

Dr. Cohen is a recipient of the NY CEO Lifetime Achievement Award and the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region. He was named Neuroinvestment’s CEO of the Year and received the Burke Award from Burke Rehabilitation Hospital for his contributions to helping people with disabilities gain independence. He has been recognized by the NYBA as its “The Cures Start Here” Business Leader of the Year, and by PharmaVOICE Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen received an M.D. from the Columbia College of Physicians & Surgeons and a B.A. degree with honors in psychology from Princeton University. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is board certified in Internal Medicine.